

Antonia Salud

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5936643/antonia-salud-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

162
citations

6
h-index

12
g-index

20
ext. papers

183
ext. citations

2.6
avg, IF

1.53
L-index

#	Paper	IF	Citations
19	Endobronchial metastatic disease: analysis of 32 cases. <i>Journal of Surgical Oncology</i> , 1996 , 62, 249-52	2.8	90
18	Prognostic significance of DNA ploidy, S-phase fraction, and P-glycoprotein expression in colorectal cancer. <i>Journal of Surgical Oncology</i> , 1999 , 72, 167-74	2.8	19
17	Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3586-3586	2.2	14
16	Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. <i>Annals of Oncology</i> , 2019 , 30, 796-803	10.3	13
15	Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. <i>Neoplasia</i> , 2018 , 20, 678-686	6.4	7
14	Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). <i>Oncologist</i> , 2019 , 24, e1115-e1122	5.7	6
13	Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: Results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2021-2029	2.2	6
12	Regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3527-3527	2.2	3
11	Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer. <i>Cancer Treatment and Research Communications</i> , 2018 , 16, 13-17	2	2
10	Clinical utility of SERUM extracelullar domain of HER2 receptor (ECD) in HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12086-e12086	2.2	1
9	Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14524-e14524	2.2	1
8	Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 501-501	2.2	0
7	[18F] Fluorodeoxyglucose positron emission (FDG-PET) in breast cancer: Clinical utility in neoadjuvant and metastatic setting.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12584-e12584	2.2	
6	LUNG cancer in Lleida: An epidemiologic study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20003-e20003	2.2	
5	TTF1 negative in non small cell lung cancer adenocarcinoma: A prognostic factor.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20004-e20004	2.2	
4	Regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC): A study of the Spanish Cooperative Group for digestive tumor therapy (TTD).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3651-TPS3651	2.2	
3	Duration of lapatinib (L)-based therapy in HER2+ metastatic breast cancer (MBC) in a single institution.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e11544-e11544	2.2	

- 2 Clinical and histopathological risk associated with brain metastasis-free survival in breast cancer..
Journal of Clinical Oncology, **2015**, 33, e11551-e11551 2.2
- 1 Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)]..
Journal of Clinical Oncology, **2016**, 34, 583-583 2.2